Semaglutide's Expanding Map: Beyond Weight Loss to Heart, Skin, and Fat Biology

Start with the head-to-head data clinicians actually care about. A real-world analysis of U.S. claims and electronic medical records compared once-weekly semaglutide against SGLT2 inhibitors in adults with uncontrolled type 2 diabetes. After inverse-probability weighting, the semaglutide cohort showed mean weight reductions of roughly 4–5 kg at one year, alongside HbA1c improvements — outcomes the authors describe as significant relative to the SGLT2 comparator, though with the usual caveats of observational design. It is the kind of evidence biohackers like to cross-reference against their own continuous glucose traces: directional, large-sample, but not a randomized trial. The PAUSE study sits squarely in the "useful but read carefully" pile.

Statins reliably crush LDL, but a stubborn fraction of cardiovascular risk hides in remnant-like particles — triglyceride-rich lipoproteins that statins barely touch. A 2025 before-and-after study in 41 patients with ischemic heart disease, all already on statins, tracked remnant-like lipoprotein (RLP) cholesterol three months after starting oral semaglutide. Mean RLP cholesterol fell from 8.52 mg/dL to 5.46 mg/dL, a statistically significant drop, with reductions also observed in the subgroup switched from DPP-4 inhibitors. The single-center trial is small and uncontrolled, but it points at a mechanism the cardiology community has been chasing: an add-on lever for residual lipid risk in patients who have already done everything their guideline-directed therapy asks of them.

This is the kind of data point that lands well with readers who treat their lipid panels like telemetry. It is also exactly the kind of finding that needs replication before anyone starts retitrating their regimen around it.

One of the most interesting papers of the year is not about humans at all. Researchers built single-cell atlases of mouse white adipose tissue across four states: lean, diet-induced obese, post-vertical-sleeve-gastrectomy, and post-semaglutide. The headline finding is that semaglutide and bariatric surgery produce different cellular signatures, even when the scale moves comparably. Some populations return toward a lean-like phenotype; others persist in an obese-like state. The comparison implies that the route to weight loss may matter for what fat tissue ends up looking like — and, by extension, for downstream metabolic behavior.

For self-experimenters, the takeaway is conceptual rather than actionable: a kilogram lost on semaglutide may not be metabolically identical to a kilogram lost via surgery or, by inference, via diet alone. It is a mouse study. It is also a useful corrective to the assumption that endpoint weight is the only variable worth tracking.

Adults with congenital heart disease (ACHD) are a population that rarely gets clean trial data — they are heterogeneous, complex, and small in number. A Mayo Clinic retrospective cohort of 70 ACHD patients prescribed semaglutide or liraglutide found that 42.9% achieved more than 5% weight loss over a mean of roughly 21 months, with better results in those with higher baseline BMI and younger age. HbA1c trended down by 0.6%. There were no significant changes in NYHA functional class or estimated glomerular filtration rate; one-third experienced side effects, mostly gastrointestinal, and about 11% discontinued or were hospitalized for adverse effects. The analysis is the first systematic look at GLP-1 use in this group and reads as cautiously encouraging: feasible and reasonably safe, with weight loss but no proven functional benefit yet.

Cardiac surgery is murkier. A 2025 review of novel antidiabetic agents in heart failure patients undergoing cardiac surgery concluded that GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors all appeared safe perioperatively in the available evidence, with SGLT2 inhibitors showing the most heart-failure-specific benefit. The authors are explicit that the literature is thin and that larger, more rigorous studies are needed before strong perioperative recommendations land. Anyone weighing this in their own care should be talking to their surgical and anesthesia teams, not to a wearable.

GLP-1 receptors are not confined to the gut and brain. A 2025 review in clinical and aesthetic dermatology surveyed the literature on GLP-1RAs and skin, and reports preliminary anti-inflammatory effects, with signals in psoriasis, hidradenitis suppurativa, and wound healing. The same review catalogs cutaneous adverse reactions — injection-site pruritus, erythema, rash — and is candid that current evidence rests on case reports and small studies. It is a frontier worth watching, not a treatment plan.

A broader review of semaglutide in obesity pulls the SUSTAIN, PIONEER, and STEP programs into one frame and emphasizes both the magnitude of benefit and the known limitations: weight regain after discontinuation, GI side effects, and substantial inter-individual variability. The synthesis is a reminder that the durability problem has not been solved — and that maintenance, not initiation, is where the next generation of evidence needs to land.

For the quantified-self reader, the honest framing is this: semaglutide is doing more than it was designed to do, in more tissues than its original label suggests, and the 2025 literature is starting to map where. The map is still rough. Edges are dotted, scale bars are approximate, and several promising regions are sketched from a single small study. That is not a reason to dismiss the work — it is a reason to read it with the same skepticism you would apply to any new dataset, and to wait for the replications that turn moderate evidence into something stronger.